Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic

Clinical Infectious Diseases

Volumn 33, Issue 5, 2001, Pages 700-705

  McNabb, JoCarol ^a   Ross, Jack W ^b   Abriola, Kenneth ^b   Turley, Christina ^b   Nightingale, Charles H ^b   Nicolau, David P ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CITY; CLINICAL ARTICLE; ETHNIC GROUP; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CONNECTICUT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; TREATMENT OUTCOME; URBAN POPULATION; VIRAL LOAD;

EID: 0035451115     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322590     Document Type: Article

References (23)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society - USA panel
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs Medical Center
4. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
5. Monitoring adherence to HIV therapy
6. Adherence to antiretroviral medications in an inner-city population
7. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy
8. Patient compliance and drug failure in protease inhibitor monotherapy
9. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial
10. Variations in the care of HIV-infected adults in the United States
11. Self-reported antiretroviral therapy in injection drug users
12. Compliance in clinical trials
13. The natural history of medication compliance in a drug trial: Limitations of pill counts
14. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
15. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
16. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
17. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy
18. Protease inhibitors in the homeless
19. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART, and survival
20. Protease inhibitors (PI) in HIV-infected homeless and marginally housed (H/M) adults
21. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
22. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites